Growth Vector Analysis of Six Segments of Novartis - Case Study Example

The term also refers to issues relating to atherosclerosis (these define diseases concerning the arterial system). Many countries around the continent have high and increasing incidents of cardiovascular diseases (Kantarjian 45). Each year, cardiovascular diseases take many American lives compared to cancer. According to Novartis, cardiovascular diseases are a significant threat and a leading cause of death to both male and female genders in most industrialized countries (Ascierto P et al 89).

In the event of these statistics, besides advocating for the importance of taking preventive measures such as decreased salt intake and avoidance of all kinds of tobacco, Novartis offers wide arrays if tools for practicing physicians for the prevention and management of the disease (WHO 33). Other ways in which Novartis tries to bring down the statistics is through the administration of prescription products which include, NeoRecormon a drug used in treating patients with anemia as a result of cancer treatment and issues relating to kidney disease (Leisinger 90).

Bezalip a lipid altering agent that is indispensable in prevention measures of cardiovascular diseases, and Torem a drug used in the treatment of renal failure, hypertension and congestive heart failure. In 2006, Novartis’ sales in drugs for the treatment of cardiovascular, related diseases accounted for 4% of the total pharmaceutical sales, a drop from 6% in 2005. The acquisition of Bezalip helped boost Novartis’ sales in 1998(Dahlgren G 42). According to the Novartis report in 2006, Bezalip was not a significant drug sale for the company as they sold it to another company and had to work on their other drugs that are NeoRecormon and Torem.

In 2001, NeoRecormon became Novartis’ best sold drug totaling to $667MM. Infective and Respiratory Segment Infective and respiratory diseases describe diseases involving virus transmission through the air or bodily fluids (R. van Tulder 32). Examples are common cold, HIV/AIDS and tuberculosis among others. The influenza virus is a crucial threat to human health as concluded by Novartis research team. Transmission of the influenza flu is through sneezing or coughing. Air molecules in the atmosphere carry the virus from one person to another thereby spreading the infectious disease.

As a result, Novartis has a prescription product referred to as Tami flu to aid in the prevention measures and treatment of the deadly virus (Kolk A 27). In reference to infectious diseases, various products are available to treat patients with Hepatitis C, HIV/AIDS and other infectious diseases. Products to treat HIV/AIDS include: Valcyte, Fuzeon, Viracept, and Fuzeon( Lipton J et al 40). Treatment for Hepatitis C is Pegasys. Other treatments for the infectious diseases include: Bactrium, Lariam, and Rocephin.

In 2006, the sale of these drugs accounted for 21% of Novartis’ sales an increase of one percent compared to 2005. The most successful sales attribute to the following drugs which include: Xolair, Tami flu, Rocephin, and Pegasys. In 2004, Tami flu fetched $302mm in sales. This was a downfall of 22% from the previous year. In 2006, Tami flu sales increased due to the increasing stockpiling of drugs in readiness of pandemics. The rise resulted to 68% increase totaling to over $2.38 billion. Oncology Segment The oncology segment deals with issues relating to cancer.

As a major player in Health Care, Novartis commits to providing the most